Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 1/2010

01-05-2010

Adoptive-Transfer Effects of Intravenous Immunoglobulin in Autoimmunity

Author: Alan H. Lazarus

Published in: Journal of Clinical Immunology | Special Issue 1/2010

Login to get access

Abstract

Intravenous immunoglobulin (IVIG) is an effective treatment for a variety of autoimmune and inflammatory conditions. The mechanism of action of IVIG remains poorly understood, but a variety of theories have been suggested. Recent studies in murine models have indicated that some of the ameliorative effects of IVIG in autoimmunity can be repeated by the adoptive transfer of leukocytes that have been primed with IVIG. The active cell component within the leukocyte cell population in immune thrombocytopenia (ITP) was determined to be CD11c+ dendritic cells. This review will highlight recent work in murine systems that indicates that the effects of IVIG can be adoptively transferred in some autoimmune diseases and inflammatory states.
Literature
1.
Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;317:1228–31.CrossRef
2.
Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)). Blut. 1984;49:29–35.CrossRefPubMed
3.
Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev. 2008;22:103–16.CrossRefPubMed
4.
Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007;26:67–78.CrossRefPubMed
5.
Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095–9.CrossRefPubMed
6.
Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest. 2005;115:155–60.PubMed
7.
Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol. 2006;135:97–100.CrossRefPubMed
8.
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fcgamma receptors on dendritic cells. Nat Med. 2006;12:688–92.CrossRefPubMed
9.
Marjon KD, Marnell LL, Mold C, Du Clos TW. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia. J Immunol. 2009;182:1397–403.PubMed
10.
Aoshi T, Zinselmeyer BH, Konjufca V, Lynch JN, Zhang X, Koide Y, et al. Bacterial entry to the splenic white pulp initiates antigen presentation to CD8+ T cells. Immunity. 2008;29:476–86.CrossRefPubMed
11.
Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008;105:19571–8.CrossRefPubMed
12.
Takeda M, Yamada H, Iwabuchi K, Shimada S, Naito M, Sakuragi N, et al. Administration of high-dose intact immunoglobulin has an anti-resorption effect in a mouse model of reproductive failure. Mol Hum Reprod. 2007;13:807–14.CrossRefPubMed
13.
Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758–65.CrossRefPubMed
14.
Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res. 2001;89:540–6.CrossRefPubMed
15.
Tha-In T, Metselaar HJ, Tilanus HW, Groothuismink ZM, Kuipers EJ, de Man RA, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood. 2007;110:3253–62.CrossRefPubMed
16.
Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+ CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715–22.CrossRefPubMed
Metadata
Title
Adoptive-Transfer Effects of Intravenous Immunoglobulin in Autoimmunity
Author
Alan H. Lazarus
Publication date
01-05-2010
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue Special Issue 1/2010
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-010-9410-9

Other articles of this Special Issue 1/2010

Journal of Clinical Immunology 1/2010 Go to the issue

OriginalPaper

The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents

OriginalPaper

Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems

OriginalPaper

Natural IgM Antibodies Against Oxidation-Specific Epitopes

OriginalPaper

Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

OriginalPaper

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

OriginalPaper

Adaptive and Innate Immune Responses in Autism: Rationale for Therapeutic Use of Intravenous Immunoglobulin
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits